Summary & Overview
HCPCS Level II J7185: Recombinant Factor VIII (Xyntha), per I.U.
HCPCS Level II code J7185 denotes the provision of recombinant factor VIII (antihemophilic factor, Xyntha) measured per international unit. This code is central to billing for replacement therapy for patients with hemophilia A and other factor VIII deficiencies and is widely used across hospital outpatient departments, infusion centers, and physician offices. Nationally, accurate coding of high-cost biologic clotting factors affects payer coverage, prior authorization workflows, and cost management for specialty drug programs.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for factor VIII replacement, typical sites of service, and common billing considerations tied to per-unit dosing. The publication outlines benchmarks and reimbursement patterns where available, highlights relevant policy updates affecting coverage and prior authorization, and summarizes operational implications for billing teams and infusion providers.
This summary is intended to inform revenue cycle, pharmacy, and clinical leadership about the billing identity and operational use of J7185, and what to expect when managing claims for recombinant factor VIII therapy.
Billing Code Overview
HCPCS Level II code J7185 represents an injection of factor VIII (antihemophilic factor, recombinant), specifically the product Xyntha, billed per international unit (I.U.).
Service Type: Therapeutic infusion/injection of clotting factor
Typical Site of Service: Hospital outpatient department, infusion center, or physician office
This code is used to report administration or provision of recombinant factor VIII for patients with hemophilia A requiring replacement therapy. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric individual with hemophilia A presenting for replacement therapy with recombinant antihemophilic factor (factor VIII) product J7185 (Xyntha) to prevent or treat bleeding. Common scenarios include acute joint or soft-tissue bleeding, perioperative prophylaxis before an invasive procedure, or routine outpatient factor replacement for bleeding prevention. The clinical workflow: the patient arrives to an infusion center, hospital outpatient clinic, emergency department, or home infusion setting; a licensed clinician verifies weight, recent factor activity levels, and target dosing; pharmacy prepares J7185 per international units ordered; nursing performs venous access, confirms product lot and expiration, documents administered IU and lot/expiration, and monitors the patient for infusion reactions. Post-infusion documentation includes dose, infusion rate, lot number, and any adverse events. Billing uses J7185 reported per international unit with appropriate modifiers for site of service, provider status, or unusual circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Rarely used; placeholder when no specific modifier applies per payer rules |